A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

MLA

Jeremy Eisele, et al. “A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation.” Transplantation and Cellular Therapy, vol. 28, Mar. 2022, pp. S298–99. EBSCOhost, https://doi.org/10.1016/s2666-6367(22)00546-2.

APA

Jeremy Eisele, Michael P. Rettig, Keith Stockerl-Goldstein, Iskra Pusic, Camille N. Abboud, Mark A. Schroeder, Feng Gao, Leah Gehrs, Armin Ghobadi, Ramzi Abboud, Matthew J. Christopher, Peter Westervelt, John F. DiPersio, Geoffrey L. Uy, Meagan A. Jacoby, Nichols Wallace, & Amanda F. Cashen. (2022). A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 28, S298–S299. https://doi.org/10.1016/s2666-6367(22)00546-2

Chicago

Jeremy Eisele, Michael P. Rettig, Keith Stockerl-Goldstein, Iskra Pusic, Camille N. Abboud, Mark A. Schroeder, Feng Gao, et al. 2022. “A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation.” Transplantation and Cellular Therapy 28 (March): S298–99. doi:10.1016/s2666-6367(22)00546-2.